Ivacaftor / tezacaftor Oral Tablet
RxNorm 1999386
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1999386 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: ivacaftor / tezacaftor Oral Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDFPrescribable
Semantic Clinical Drug Form (SCDF):
Ivacaftor / tezacaftor Oral Tablet
(Atom ID: 9732642)
Patient Education
Tezacaftor and Ivacaftor
The combination of tezacaftor and ivacaftor is used along with ivacaftor to treat certain types of cystic fibrosis (an inborn disease that causes problems with breathing, digestion, and reproduction) in adults and children 6 years of age and older. Tezacaftor and ivacaftor should be used only in people with a certain genetic make-up. Your doctor may order a blood test to help decide if this medication is right for you. Tezacaftor is in a class of medications called cystic fibrosis transmembrane conductance regulator (CFTR) correctors. Ivacaftor is in a class of medications called cystic fibrosis transmembrane conductance regulator (CFTR) potentiators. Both of these medications work by improving the function of a protein in the body to decrease the build-up of thick mucus in the lungs and improve other cystic fibrosis symptoms.
[Learn More]
* Please review the disclaimer below.